Search

AbCellera Biologics Inc

Slēgts

SektorsVeselības aprūpe

11.33 -8.48

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

11.26

Max

12.38

Galvenie mērījumi

By Trading Economics

Ienākumi

-55M

-99M

Pārdošana

-4.3M

4.1M

EPS

-0.18

Peļņas marža

-2,434.37

Darbinieki

562

EBITDA

-645K

-42M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+38.47% upside

Dividendes

By Acuity

Nākamie ieņēmumi

2026. g. 5. nov.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

1.9B

3.7B

Iepriekšējā atvēršanas cena

19.81

Iepriekšējā slēgšanas cena

11.33

Ziņu noskaņojums

By Acuity

50%

50%

126 / 340 Rangs Healthcare

AbCellera Biologics Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 28. aug. 23:01 UTC

Abcellera Biologics Inc shares are trading lower in after-market hours. No specific company news was identified to explain this movement.

2026. g. 26. aug. 19:56 UTC

Correlated Moves

Abcellera Biologics Inc shares are lower today, influenced by declines in the ARK Genomic Revolution ETF and broader genomic sector trends.

2026. g. 25. aug. 23:06 UTC

Abcellera Biologics Inc. shares declined slightly in after-market trading, despite remaining above their 20-day moving average after recent gains.

2026. g. 24. aug. 23:36 UTC

Social Media

Abcellera Biologics Inc. is rising in after-market trading, fueled by a director's $570,000 insider purchase near its 52-week high, indicating insider confidence.

2026. g. 21. aug. 19:36 UTC

Social Media
Correlated Moves

Abcellera Biologics Inc shares are lower today amid broader market pressures. The decline coincides with a drop in U.S. Treasury yields and infrastructure-related assets.

2026. g. 20. aug. 19:16 UTC

Social Media
Correlated Moves

Abcellera shares lower amid broader market pressures, influenced by SPDR ETF.

2026. g. 19. aug. 23:02 UTC

Social Media

Abcellera Biologics Inc shares are higher in after-hours trading, reflecting increased investor interest and social media discussions about the stock's potential at $12.20.

2026. g. 18. aug. 19:56 UTC

Correlated Moves

Abcellera Biologics Inc shares are lower, influenced by declines in small-cap stocks and rising Treasury yields amid ongoing inflation concerns.

2026. g. 17. aug. 23:06 UTC

Correlated Moves

Abcellera Biologics Inc shares are lower in after-market trading, following unusual volatility and a decline in the Russell 2000 Index.

2026. g. 14. aug. 19:44 UTC

Social Media
News

Abcellera Biologics Inc shares are higher today amid increased call option volume and discussions of insider buying, with the stock trading around $10.50.

2026. g. 13. aug. 19:31 UTC

Social Media
News

Abcellera Biologics priced an oversubscribed offering at $9.75 per share, aiming to raise $200 million. Shares are higher since Wednesday's close despite earlier pullback.

2026. g. 12. aug. 20:02 UTC

Social Media
News

Abcellera Biologics has launched a $200 million public offering to support its lead program, while shares are advancing during today's trading session.

2026. g. 11. aug. 22:51 UTC

News

Abcellera Biologics announced a $200 million public offering, contributing to a decline in after-market trading amid investor concerns over potential dilution.

2026. g. 10. aug. 23:06 UTC

Correlated Moves
Event
News
Social Media

Abcellera Biologics reported positive Phase 2 trial results for ABCL635, but shares are lower in after-market hours amid broader market declines.

2026. g. 8. aug. 00:06 UTC

Event
News

Abcellera Biologics will release Phase 2 trial results for ABCL635 on August 10, 2026. Shares are trading higher in after-market hours.

2026. g. 7. aug. 23:21 UTC

Social Media
News
Event

Abcellera Biologics will release Phase 2 trial results for ABCL635 on August 10, 2026. Shares are sharply higher in after-market trading amid positive investor sentiment.

2026. g. 6. aug. 23:06 UTC

Abcellera Biologics Inc. shares are lower in after-market trading, despite earlier reaching a session high and remaining above the 20-day moving average.

2026. g. 5. aug. 23:02 UTC

Social Media
News

Abcellera Biologics shares are lower in after-market hours following disappointing Q2 results, with an EPS of -$0.18 and revenue of $4.1 million.

2026. g. 3. aug. 19:36 UTC

Correlated Moves

Abcellera Biologics Inc shares are higher as market sentiment improves following President Trump's cancellation of a military strike on Iran.

2026. g. 31. jūl. 19:33 UTC

Correlated Moves
Social Media

Abcellera Biologics Inc is declining during Friday's session, reflecting broader biotech sector weakness amid rising yields and inflation concerns.

2026. g. 30. jūl. 23:41 UTC

Correlated Moves

Abcellera Biologics shares are lower in after-market trading, reflecting broader market volatility following the Federal Reserve's decision to maintain interest rates.

2026. g. 29. jūl. 23:51 UTC

Abcellera Biologics Inc. shares were roughly flat in after-market hours, with no specific news identified. The stock is down significantly from last month's close.

2026. g. 28. jūl. 19:41 UTC

News

Abcellera Biologics is rising, driven by gains in the Life Sciences Tools & Services sector and positive trends in the antibody therapeutics market.

2026. g. 27. jūl. 19:46 UTC

Correlated Moves

Abcellera Biologics Inc shares are higher, reflecting a modest increase since Friday's close. Broader market gains may influence sentiment in life sciences.

2026. g. 24. jūl. 23:46 UTC

Abcellera Biologics Inc shares are higher in after-market hours, showing resilience despite recent challenges in the bond market and declining prices.

2026. g. 22. jūl. 20:06 UTC

Abcellera Biologics Inc shares are lower today, reflecting broader market trends amid uncertainty ahead of the Federal Reserve meeting on July 29.

2026. g. 21. jūl. 23:06 UTC

Correlated Moves

Abcellera Biologics shares higher in after-market trading, maintaining strong performance since Tuesday's close, despite being below its 20-day moving average.

2026. g. 20. jūl. 23:16 UTC

Abcellera Biologics Inc. shares are roughly flat in after-market trading, remaining about 16.33% below their 20-day moving average.

Salīdzinājums

Cenas izmaiņa

AbCellera Biologics Inc Prognoze

Cenas mērķis

By TipRanks

38.47% augšup

Prognoze 12 mēnešiem

Vidējais 17.17 USD  38.47%

Augstākais 30 USD

Zemākais 9 USD

Pamatojoties uz 7 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi AbCellera Biologics Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

7 ratings

7

Pirkt

0

Turēt

0

Pārdot

Noskaņojums

By Acuity

126 / 340 Rangs Veselības aprūpe

Ziņu noskaņojums

Neutral

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Zem vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
help-icon Live chat